The movement toward transparency is global, touching almost every aspect of society. Whether the topic is NSA eavesdropping in the U.S. or banking practices in the European Union, transparency and accountability go hand in hand. The pharma industry is no different.
Flush with cash and high stock prices, companies are buying up the competition at levels not...
A new report explains why you will soon be able to get a clearer picture about your doctor's...
Eisai and Biogen Idec announced have entered into a collaboration to develop and commercialize...
President Barack Obama's budget pushes Health and Human Services spending over $1 trillion for the first time, reflecting an aging population as well as expanded coverage for younger people through the new health law.
The right combination of equipment, capsule, and formulation can bolster yields, speed up filling, and cut downtime for faster market delivery and higher profits.
Teva Pharmaceutical has announced the approval of the generic equivalent to Evista® (Raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.
Dynavax Technologies Corp. has announced a $5.4 million milestone payment from its collaborator, AstraZeneca.
Theravance announced today that its plan to separate its businesses into two independent, publicly traded companies is now expected to be completed during the second quarter 2014.
Olympus Biotech today announced the initiation of an aggressive transaction process to find a buyer of its West Lebanon, NH manufacturing facility over the next 90 days. In recent months, the Company has received interest from buyers and contract manufacturing organization (CMO) partners, but no deal has been consummated yet.
A bill to create a state loan program for large economic development projects cleared two committees in the Wyoming House on Friday. Supporters say it offers the state a way to entice a large pharmaceutical company to expand a laboratory in Cody.
Hospitals, health care providers, medical professional groups accounted for the bulk of the spending — $60.6 million since 2007 — compared with medical, dental and mental health insurance providers ($18.8 million), and pharmaceutical companies ($23.7 million).
Dendreon Corporation today announced that it plans to make PROVENGE ® (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.
Bayer AG says its net profit jumped by almost a third last year to 3.19 billion euros ($4.35 billion) as sales hit a record high.
U.S. hospitals are coping better with ongoing shortages of hundreds of medications, but a new survey indicates that obtaining drugs from alternate sources is costing them a lot of money they can't spare.
Valeant Pharmaceuticals is seeing more clearly the merits of its acquisition last summer of eye care company Bausch and Lomb and remains on the hunt for another big acquisition this year.
A bill that started out as an effort to direct a state loan to a New Jersey pharmaceutical company and later morphed into an ambitious new state business loan program cleared the Wyoming Senate on Tuesday.
A lawyer for two drug companies told the Arkansas Supreme Court that the state improperly relied on federal regulations in a lawsuit that resulted in a $1.2 billion award over the companies' marketing of an antipsychotics drug.
Shares of Mylan Inc. jumped in premarket trading Thursday as the generic drugmaker reported an 11 percent increase in its fourth-quarter earnings, topping expectations despite a rise in expenses.
Moody's Investors Service upgraded Biogen Idec's credit rating on Wednesday, saying the biotech drugmaker should continue to report strong sales of its multiple sclerosis drugs.
Lilly said that a once-weekly, 1.5-milligram dose of dulaglutide was not inferior to a daily, 1.8 milligram dose of Novo Nordisk's Victoza in a study of nearly 600 patients who were already taking metformin, an older diabetes treatment.
Eli Lilly is buying a privately held, poultry vaccine maker to strengthen its Elanco animal health subsidiary. No terms were released, but Lilly said Monday that its 2014 earnings forecast will be trimmed due to acquisition costs.
Endo Health will pay almost $193 million to resolve claims that it improperly marketed the shingles treatment Lidoderm for unapproved uses like treating lower back pain.
Nuevolution A/S has entered an exclusive license agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development.
The new five-year agreement, which extends through March 2019, creates efficiencies for both companies by leveraging the strength of Rite Aid as one of the leading national drugstore chains in the United States, and McKesson as a leader in pharmaceutical sourcing and supply chain management.
CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.
Actavis PLC says it will acquire fellow drugmaker Forest Laboratories Inc. in a cash-and-stock deal worth about $25 billion.
AVEO and Astellas to End Collaboration & License Agreement for Development and Commercialization of TivozanibFebruary 14, 2014 8:04 am | News | Comments
AVEO Oncology and Astellas Pharma Inc. today announced the companies will end their worldwide collaboration and license agreement for the development and commercialization of investigational agent tivozanib.
Study: Pharmaceutical Pricing Studies Increasingly Focus on Existing Competitors and Relevant PayersFebruary 12, 2014 2:20 pm | News | Comments
In a recent study, when evaluating a product’s optimal price, 84% of surveyed pharmaceutical companies focus on obtaining information about competitor companies and products.
- Page 1